ClinicalTrials.gg
Active, not recruitingNCT04057794PDGENEUpdated Jul 14, 2023

PDGeneration: Mapping the Future of Parkinson's Disease

An interventional study of Lab Assay for seven genetic variants for Parkinson's Disease and Lab Assay for seven genetic variants for Parkinson's Disease in Parkinson's Disease and Parkinsonism, sponsored by Parkinson's Foundation. Active, not recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by Parkinson's Foundation · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,982
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
8th of 1,257
1,982 · median 36
Started
2019
with 104 others
No phase
586 of 1,650
147 open now
Primary completion
2021-12
later than 7 of 384 live
Registered
992nd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 8th largest by enrollment of the 1,257 interventional ones that give a count, is one of 105 that started in 2019, is one of 586 with no phase, reaches primary completion later than 7 of the 384 other live ones, and was the 992nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).

Read the detailed description

The purpose of this study is to evaluate how offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing for Parkinson's Disease (PD) genes to people with Parkinson's Disease impacts clinical care and potential enrollment in clinical trials. This multi-center study will assess the impact and satisfaction of the mode of genetic counseling by comparing counseling conducted by a clinician versus centralized genetic counseling conducted through Indiana University. The study will also assess knowledge gained by administering a knowledge survey pre- and post-genetic testing. All genetic test results will be returned to participants through a genetic counseling visit.

03

Conditions studied

  • Parkinson's Disease and Parkinsonism

Keywords

  • Parkinson's
  • Genetics
  • PD Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
  2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for Glucosylceramidase Beta (GBA), LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
  3. Capacity to give full in writing, and have read and signed the informed consent forms (ICFs) based on clinician's determination.
  4. Able to perform study activities (including completion of either online, in-person or paper surveys).
  5. Individuals must speak and understand the language of the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
  2. Individuals who have received a blood transfusion within the past 3 months.
  3. Individuals who have active hematologic such as lymphoma or leukemia.
  4. Individuals who have had a bone marrow transplant within the past 5 years.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,982 participants (actual)

Study arms

  • Active comparator
    Site-Based Genetic Counseling

    Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.

    Device: Lab Assay for seven genetic variants for Parkinson's Disease

  • Active comparator
    Centralized Genetic Counseling

    Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.

    Device: Lab Assay for seven genetic variants for Parkinson's Disease

Interventions

  • DeviceLab Assay for seven genetic variants for Parkinson's Disease

    Counseling provided to participant by site clinician/physician/genetic counselor.

  • DeviceLab Assay for seven genetic variants for Parkinson's Disease

    Counseling provided to participant by centralized genetic counseling group at Indiana University.

06

What researchers measure

Primary outcomes

  1. Feasibility of genetic testing and counseling

    The total number of participants who receive genetic testing and counseling.

    Time frame: up to 24 weeks

  2. Impact Evaluation

    The impact of knowledge gained by people with Parkinson's by assessing returned survey responses regarding their behavior and follow-up to clinical care after receipt of genetic counseling.

    Time frame: up to 6 months

  3. Satisfaction Comparison

    Differences in satisfaction of receiving genetic test results and genetic counseling by enrolling site (clinician/genetic counselor) or centralized counseling group using the Clinical Genetic Counseling Satisfaction Score.

    Time frame: up to 6 months

Secondary outcomes

  1. Number of participants that enroll in precision medicine trials

    Number of participants that enroll in precision medicine trials

    Time frame: up to 12 months

  2. Time it takes between first contact to the return of genetic test results

    Number of weeks it takes between participant consent to return of genetic test results.

    Time frame: up to 12 months

07

Study locations

13 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Dec 2021, 27 months.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 27 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 15, 2019
StartActual
Aug 15, 2019
Primary completionActual
Dec 1, 2021
CompletionEst.
Apr 15, 2025
Last update
Jul 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04057794
Lead sponsor
Parkinson's Foundation
Collaborators
Fulgent Laboratories, Indiana University, The Parkinson Study Group, Navitas Clinical Research, Inc
Responsible party
Sponsor
First posted
Aug 15, 2019
Start date
Aug 15, 2019
Primary completion
Dec 1, 2021
Completion
Apr 15, 2025 (estimated)
Last update
Jul 14, 2023

Study contacts

Roy N Alcalay, MD, MS
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion